1245603-92-2

1245603-92-2 structure

Name: PF 04937319
Chemical Name: 7E99B9ZM19
CAS Number: 1245603-92-2
Molecular Formula: C₂₂H₂₀N₆O₄
Molecular Weight: 432.432
Catalog: Signaling Pathways Metabolic Enzyme/Protease Glucokinase
Create Date: 2018-07-11 02:24:33
Modify Date: 2026-07-23 18:12:40
PF-04937319 is a glucokinase activator (GKA) with EC50 value of 154.4 μM, one of the most promising strategies for the treatment of type 2 diabetes mellitus[1].PF-04937319 is designed to maintain glucose-lowering efficacy while mitigating the risk of hypoglycaemia observed with many other GKAs[2].

Name	7E99B9ZM19
Synonyms	EOS-61370 N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)cbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-cboxamide PF-04937319 PF-04937319[PZ0320] N,N-Dimethyl-5-[[2-methyl-6-[[(5-methyl-2-pyrazinyl)amino]carbonyl]-4-benzofuranyl]oxy]-2-pyrimidinecboxamide Inhibitor,PF-04937319,Hexokinase IV,PF 04937319,PF04937319,Hexokinase D,inhibit,Glucokinase N,N-Dimethyl-5-({2-methyl-6-[(5-methyl-2-pyrazinyl)carbamoyl]-1-benzofuran-4-yl}oxy)-2-pyrimidinecarboxamide 2-Pyrimidinecboxamide, N,N-dimethyl-5-[[2-methyl-6-[[(5-methyl-2-pyrazinyl)amino]carbonyl]-4-benzofuranyl]oxy] Nerigliatin (PF-04937319) PF-04937319, 10 mM in DMSO N,N-Dimethyl-5-[2-methyl-6-[N-(5-methylpyrazin-2-yl)cbamoyl]-1-benzofuran-4-yloxy]pyrimidine-2-cboxamide N,N-Dimethyl-5-({2-Methyl-6-[(5-Methylpyrazin-2-Yl)carbamoyl]-1-Benzofuran-4-Yl}oxy)pyrimidine-2-Carboxamide PF-04937319 >= (HPLC)

Description	PF-04937319 is a glucokinase activator (GKA) with EC50 value of 154.4 μM, one of the most promising strategies for the treatment of type 2 diabetes mellitus[1].PF-04937319 is designed to maintain glucose-lowering efficacy while mitigating the risk of hypoglycaemia observed with many other GKAs[2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Glucokinase Research Areas >> Metabolic Disease
Target	EC50: 154.4 μM (GSA) (PF-04937319)[1]
References	[1]. Dzyurkevich MS, et al. Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus. Sci Rep. 2017 Nov 22;7(1):16072. [2]. Amin NB, et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9.

RIDADR	NONH for all modes of transport